CT Man Diagnosed with Alzheimer’s Discovers Urgent Breakthroughs

UPDATE: A Connecticut man, Lee Ross, has received a life-altering diagnosis of early onset Alzheimer’s disease, but recent medical breakthroughs are offering a glimmer of hope. Ross, 61, a former attorney, began experiencing troubling cognitive issues, prompting him to seek answers. His diagnosis was confirmed after extensive tests and brain scans, revealing a buildup of amyloid plaque in his brain.

“I just knew that something wasn’t right,” Ross said. His journey to diagnosis was fraught with challenges, as he struggled against suggestions that his symptoms were merely due to anxiety. After persistent advocacy for his health, he received the diagnosis early this year, leading to significant life changes.

Ross, who retired from his position as legislative director at the state judicial branch, described the moment of diagnosis as “devastating.” He emphasized the urgency of recognizing early symptoms, stating, “All of a sudden I am an Alzheimer’s patient.”

But hope arrived in the form of new treatments. Ross learned about Leqembi, a groundbreaking drug developed by Eisai in partnership with Biogen, which has shown promise in slowing the progression of Alzheimer’s. According to the manufacturer, Leqembi is designed specifically for individuals with early Alzheimer’s disease, including mild cognitive impairment.

“I didn’t hesitate for a second,” Ross declared regarding his decision to start the treatment. “The benefits of this far outweigh the risks.” This sentiment reflects a growing awareness and optimism surrounding Alzheimer’s therapies, as conversations about treatment options become increasingly vital.

Ross, together with his family, made the informed choice to pursue treatment despite potential side effects, including headaches and temporary brain swelling. “The alternative is just not an option,” he stressed, highlighting that he previously experienced some swelling but has since resumed the medication.

Officials from the Alzheimer’s Association, including Kristen Cusato, director of communications for the Connecticut and Rhode Island Chapter, noted that Leqembi represents a major advancement in Alzheimer’s care. “It creates a whole new world to treat patients,” Cusato stated, emphasizing that early detection can significantly improve quality of life for families.

According to the Association, there are approximately 80,000 individuals living with Alzheimer’s in Connecticut and around 250,000 people diagnosed with younger onset Alzheimer’s across the United States. The majority of Alzheimer’s patients are over 65, but early onset cases, like Ross’s, are becoming increasingly recognized.

In a move to raise awareness, Ross has initiated a team for the upcoming Walk to End Alzheimer’s in Greater Hartford, scheduled for October 19, 2023, at Rentschler Field. The event opens at 9 a.m., with a special Promise Garden ceremony at 10 a.m. Ross hopes his story will inspire others to seek early testing and treatment options.

“I just felt, if I could do something, if I could maybe tell my story, perhaps others would consider getting tested,” Ross shared. His message resonates with many, as early testing can lead to timely interventions and a better quality of life.

As the Alzheimer’s Association continues to advocate for education and awareness, Cusato emphasized the importance of taking charge of brain health. “If you are in the early part of the disease, there are a lot of options for you. We really want people to take their concerns to a doctor,” she urged.

For those interested in more information on Alzheimer’s disease, the Alzheimer’s Association offers a 24/7 Helpline at 1-800-272-3900 and resources on their website at alz.org/ct. The urgency of this health crisis demands immediate action and understanding, making stories like Ross’s essential to spreading awareness.

As the medical community continues to uncover new treatments and insights into Alzheimer’s, patients and families are urged to remain hopeful and proactive in their care journeys.